Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer

Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biolo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of experimental & clinical cancer research Vol. 41; no. 1; pp. 186 - 14
Main Authors: de Miguel-Perez, Diego, Russo, Alessandro, Arrieta, Oscar, Ak, Murat, Barron, Feliciano, Gunasekaran, Muthukumar, Mamindla, Priyadarshini, Lara-Mejia, Luis, Peterson, Christine B., Er, Mehmet E., Peddagangireddy, Vishal, Buemi, Francesco, Cooper, Brandon, Manca, Paolo, Lapidus, Rena G., Hsia, Ru-Ching, Cardona, Andres F., Naing, Aung, Kaushal, Sunjay, Hirsch, Fred R., Mack, Philip C., Serrano, Maria Jose, Adamo, Vincenzo, Colen, Rivka R., Rolfo, Christian
Format: Journal Article
Language:English
Published: London BioMed Central 02.06.2022
BioMed Central Ltd
Springer Nature B.V
BMC
Subjects:
Apoptosis
B7-H1 Antigen - metabolism
Biomarkers
Biomedical and Life Sciences
Biomedicine
Biopsy
Cancer Research
Cancer therapies
Carcinoma, Non-Small-Cell Lung - pathology
Development and progression
Extracellular vesicles
Extracellular Vesicles - metabolism
Humans
Immune checkpoint inhibitors
Immune Checkpoint Inhibitors - therapeutic use
Immune response
Immunology
Immunotherapy
Lung cancer
Lung cancer, Non-small cell
Lung cancer, Small cell
Lung Neoplasms
Medical imaging
Metastasis
NSCLC
Oncology
Patient outcomes
PD-L1
Performance evaluation
Prognosis
Prospective Studies
Retrospective Studies
Software
Statistical analysis
Tumors
United States > US
Extracellular vesicles
PD-L1
Biomarkers
NSCLC
Immunotherapy
ISSN:1756-9966, 0392-9078, 1756-9966
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer. However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers. Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs. Methods Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively. Results As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1 expression, the commonly used biomarker, was not predictive neither for durable response nor survival. Conclusion These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC who would experience durable benefit from ICIs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:1756-9966
0392-9078
1756-9966
DOI:10.1186/s13046-022-02379-1